Index RUT
P/E -
EPS (ttm) -3.39
Insider Own 63.18%
Shs Outstand 47.67M
Perf Week -0.55%
Market Cap 90.11M
Forward P/E -
EPS next Y -1.73
Insider Trans -0.08%
Shs Float 18.33M
Perf Month 0.56%
Income -156.27M
PEG -
EPS next Q -0.42
Inst Own 47.20%
Short Float 6.85%
Perf Quarter 6.47%
Sales 0.00M
P/S -
EPS this Y 18.93%
Inst Trans 31.29%
Short Ratio 3.87
Perf Half Y -87.09%
Book/sh 4.16
P/B 0.44
EPS next Y 29.98%
ROA -55.47%
Short Interest 1.26M
Perf Year -83.55%
Cash/sh 4.92
P/C 0.37
EPS next 5Y -
ROE -73.77%
52W Range 1.55 - 20.22
Perf YTD -88.72%
Dividend Est. -
P/FCF -
EPS past 5Y -241.80%
ROI -68.90%
52W High -91.05%
Beta 0.79
Dividend TTM -
Quick Ratio 5.14
Sales past 5Y 0.00%
Gross Margin -
52W Low 16.77%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 5.14
EPS Y/Y TTM -37.60%
Oper. Margin 0.00%
RSI (14) 46.26
Volatility 3.70% 3.25%
Employees 90
Debt/Eq 0.25
Sales Y/Y TTM -
Profit Margin -
Recom 3.00
Target Price 3.33
Option/Short No / Yes
LT Debt/Eq 0.11
EPS Q/Q -12.47%
Payout -
Rel Volume 0.22
Prev Close 1.84
Sales Surprise -
EPS Surprise -6.22%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 324.09K
Price 1.81
SMA20 -0.47%
SMA50 -0.23%
SMA200 -80.76%
Trades
Volume 70,051
Change -1.63%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-09-24 Downgrade
Stifel
Buy → Hold
$34 → $3
Jul-09-24 Downgrade
Leerink Partners
Outperform → Market Perform
$28 → $2
Jul-09-24 Downgrade
H.C. Wainwright
Buy → Neutral
$28 → $2
Jul-08-24 Downgrade
JP Morgan
Overweight → Neutral
$24 → $5
Jul-08-24 Downgrade
Guggenheim
Buy → Neutral
Dec-13-23 Initiated
H.C. Wainwright
Buy
$28
Oct-14-24 12:00PM
Aug-08-24 07:20PM
Aug-01-24 11:53AM
(Pharmaceutical Technology)
Jul-31-24 04:00PM
Jul-29-24 09:35AM
09:35AM
Loading…
Jul-11-24 09:35AM
Jul-09-24 10:19AM
Jul-08-24 12:36PM
12:17PM
08:42AM
08:16AM
07:30AM
May-23-24 02:15AM
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
Loading…
04:05PM
Apr-14-24 12:52PM
Apr-06-24 01:33AM
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
Dec-19-23 01:01PM
Dec-05-23 09:48PM
Nov-30-23 09:55AM
11:03AM
Loading…
Nov-21-23 11:03AM
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
(American City Business Journals) -7.26%
-10.17%
07:00AM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kohli Aditya Director May 20 '24 Sale 15.45 6,000 92,689 776,878 May 22 05:40 PM Kohli Aditya Director May 22 '24 Sale 14.73 6,000 88,372 764,878 May 22 05:40 PM Kohli Aditya Director May 21 '24 Sale 14.21 6,000 85,230 770,878 May 22 05:40 PM Kohli Aditya Director May 02 '24 Sale 14.01 6,000 84,081 783,601 May 03 07:12 PM Kohli Aditya Director May 03 '24 Sale 14.15 723 10,233 782,878 May 03 07:12 PM Kohli Aditya Director May 01 '24 Sale 14.03 175 2,456 789,601 May 03 07:12 PM Frazier Life Sciences X, L.P. 10% Owner Apr 04 '24 Buy 14.50 8,850 128,325 8,544,187 Apr 08 04:22 PM Kohli Aditya Director Apr 03 '24 Sale 14.93 6,000 89,582 801,776 Apr 05 05:48 PM Kohli Aditya Director Apr 04 '24 Sale 14.71 6,000 88,245 795,776 Apr 05 05:48 PM Kohli Aditya Director Apr 05 '24 Sale 14.44 6,000 86,640 789,776 Apr 05 05:48 PM McLoughlin Sean Chief Operating Officer Mar 28 '24 Buy 16.98 1,250 21,225 1,250 Apr 01 04:08 PM Kohli Aditya Director Mar 18 '24 Sale 17.66 6,000 105,937 819,776 Mar 20 06:27 PM Kohli Aditya Director Mar 19 '24 Sale 17.42 6,000 104,492 813,776 Mar 20 06:27 PM Kohli Aditya Director Mar 20 '24 Sale 16.42 6,000 98,533 807,776 Mar 20 06:27 PM Kohli Aditya Director Mar 06 '24 Sale 18.95 6,000 113,701 837,776 Mar 08 06:38 PM Kohli Aditya Director Mar 08 '24 Sale 18.66 6,000 111,959 825,776 Mar 08 06:38 PM Kohli Aditya Director Mar 07 '24 Sale 18.37 6,000 110,213 831,776 Mar 08 06:38 PM Kohli Aditya Director Feb 22 '24 Sale 15.05 6,000 90,312 843,776 Feb 22 05:20 PM Kohli Aditya Director Feb 21 '24 Sale 14.92 6,000 89,495 849,776 Feb 22 05:20 PM Kohli Aditya Director Feb 20 '24 Sale 14.88 6,000 89,272 855,776 Feb 22 05:20 PM Kohli Aditya Director Feb 12 '24 Sale 15.32 6,000 91,921 861,776 Feb 14 04:22 PM Kohli Aditya Director Feb 08 '24 Sale 14.93 8,866 132,383 812,878 Feb 12 08:06 PM Maltbie Shane Chief Financial Officer Feb 08 '24 Sale 14.93 3,576 53,395 40,656 Feb 12 07:51 PM HERSHBERG ROBERT See Remarks Feb 08 '24 Sale 14.93 11,597 173,161 953,831 Feb 12 07:47 PM Borkowski Astrid Chief Medical Officer Feb 08 '24 Sale 14.93 3,933 58,726 161,260 Feb 12 07:35 PM Borkowski Astrid Chief Medical Officer Dec 15 '23 Sale 15.50 10,000 155,000 165,193 Dec 18 05:34 PM Borkowski Astrid Chief Medical Officer Dec 04 '23 Sale 14.50 10,000 145,000 175,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Dec 01 '23 Sale 14.20 10,000 142,000 185,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Nov 17 '23 Sale 14.00 10,000 140,000 195,193 Nov 20 04:53 PM Borkowski Astrid Chief Medical Officer Nov 08 '23 Sale 13.00 5,000 65,000 205,193 Nov 13 05:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite